2 results
Approved WMOCompleted
Cohort 1 (HER2-positive/amplified MBC): MCLA-128 + trastuzumab ± vinorelbine Primary objective:• Evaluate efficacy of MCLA-128 combined with trastuzumab ± vinorelbine in terms of clinical benefit rate (CBR) at 24 weeks based on RECIST 1.1 (per…
Approved WMOCompleted
To evaluate tailoring components in a web application for THA patients and to refine guidelines for tailored web applications for patients.Secondary objectives:- To assess how and how often THA patients use a prototype of the tailored web…